Opendata, web and dolomites

BREATHE SIGNED

Biochemically modified messenger RNA encoding nucleases for in vivo gene correction of severe inherited lung diseases

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 BREATHE project word cloud

Explore the words cloud of the BREATHE project. It provides you a very rough idea of what is the project "BREATHE" about.

vehicle    barriers    inherited    efficient    single    mediated    risk    correction    edge    contribution    thousands    cells    date    lungs    diseases    treatment    cure    efficacy    alveolar    nucleotide    transcripts    integration    nec    models    severe    ten    suited    immune    therapy    stem    competitive    successful    rna    messenger    terminally    pulmonary    critical    mouse    causing    therapeutically    ultimate    permanent    data    endogenous    uniquely    congenital    modified    eliminates    nucleases    quadrupled    balanced    clinic    mutations    deficient    deficiency    incorporating    therapeutic    vectors    surfactant    underlying    efficiency    differentiated    mrna    span    sp    saving    translation    mice    lung    nuclease    first    goals    gene    safety    disease    model    nucleotides    feel    site    vivo    transfection    humanized    cystic    valuable    people    fatal    generate    safe    amounts    encoded    dna    fibrosis    genetically    chemically    life    genomic    cell    mimic    prevented    group    repeated    engineering    protein    physical    cf   

Project "BREATHE" data sheet

The following table provides information about the project.

Coordinator
EBERHARD KARLS UNIVERSITAET TUEBINGEN 

Organization address
address: GESCHWISTER-SCHOLL-PLATZ
city: TUEBINGEN
postcode: 72074
website: www.uni-tuebingen.de

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Germany [DE]
 Project website http://www.kormann-lab.de
 Total cost 1˙497˙125 €
 EC max contribution 1˙497˙125 € (100%)
 Programme 1. H2020-EU.1.1. (EXCELLENT SCIENCE - European Research Council (ERC))
 Code Call ERC-2014-STG
 Funding Scheme ERC-STG
 Starting year 2015
 Duration (year-month-day) from 2015-04-01   to  2020-03-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    EBERHARD KARLS UNIVERSITAET TUEBINGEN DE (TUEBINGEN) coordinator 1˙497˙125.00

Map

 Project objective

Surfactant Protein B (SP-B) deficiency and Cystic Fibrosis (CF) are severe, fatal inherited diseases affecting the lungs of ten thousands of people, for which there is currently no available cure. Although gene therapy is a promising therapeutic approach, various technical problems, including numerous physical and immune-mediated barriers, have prevented successful application to date. My recent studies were the first to demonstrate the life-saving efficacy of repeated pulmonary delivery of chemically modified messenger RNA (mRNA) in a mouse model of congenital SP-B deficiency. By incorporating balanced amounts of modified nucleotides to mimic endogenous transcripts, I developed a safe and therapeutically efficient vehicle for lung transfection that eliminates the risk of genomic integration commonly associated with DNA-based vectors. I also assessed the delivery of mRNA-encoded site-specific nucleases to the lung to facilitate targeted gene correction of the underlying disease-causing mutations. In comprehensive studies, we show that a single application of nucleases encoded by nucleotide-modified RNA (nec-mRNA) can generate in vivo correction of terminally differentiated alveolar type II cells, which more than quadrupled the life span of SP-B deficient mice. Together with my working group, I aim to further develop this technology to enhance the efficiency and safety of nec-mRNA-mediated in vivo lung stem cell targeting, providing an ultimate cure by permanent correction. Specifically, we will test this approach in humanized mouse models of SP-B deficiency and CF. Developing and genetically engineering humanized models in vivo will be a critical step towards the safe translation of mRNA based nuclease technology to the clinic. With my competitive edge in lung-transfection technology and strong data, I feel that my group is uniquely suited to achieve these goals and to make a highly valuable contribution to the development of an efficient treatment.

 Publications

year authors and title journal last update
List of publications.
2018 Sriram Vaidyanathan, Krist T. Azizian, A.K.M. Ashiqul Haque, Jordana M. Henderson, Ayal Hendel, Sabrina Shore, Justin S. Antony, Richard I. Hogrefe, Michael S.D. Kormann, Matthew H. Porteus, Anton P. McCaffrey
Uridine Depletion and Chemical Modification Increase Cas9 mRNA Activity and Reduce Immunogenicity without HPLC Purification
published pages: 530-542, ISSN: 2162-2531, DOI: 10.1016/j.omtn.2018.06.010
Molecular Therapy - Nucleic Acids 12 2019-12-17
2019 Itishri Sahu, A.K.M. Ashiqul Haque, Brian Weidensee, Petra Weinmann, Michael S.D. Kormann
Recent Developments in mRNA-Based Protein Supplementation Therapy to Target Lung Diseases
published pages: 803-823, ISSN: 1525-0016, DOI: 10.1016/j.ymthe.2019.02.019
Molecular Therapy 27/4 2019-12-17
2018 Justin S. Antony, Ngadhnjim Latifi, A. K. M. Ashiqul Haque, Andrés Lamsfus-Calle, Alberto Daniel-Moreno, Sebastian Graeter, Praveen Baskaran, Petra Weinmann, Markus Mezger, Rupert Handgretinger, Michael S. D. Kormann
Gene correction of HBB mutations in CD34+ hematopoietic stem cells using Cas9 mRNA and ssODN donors
published pages: , ISSN: 2194-7791, DOI: 10.1186/s40348-018-0086-1
Molecular and Cellular Pediatrics 5/1 2019-12-17
2018 A. K. M. Ashiqul Haque, Alexander Dewerth, Justin S. Antony, Joachim Riethmüller, Georg R. Schweizer, Petra Weinmann, Ngadhnjim Latifi, Hanzey Yasar, Nicoletta Pedemonte, Elvira Sondo, Brian Weidensee, Anjali Ralhan, Julie Laval, Patrick Schlegel, Christian Seitz, Brigitta Loretz, Claus-Michael Lehr, Rupert Handgretinger, Michael S. D. Kormann
Chemically modified hCFTR mRNAs recuperate lung function in a mouse model of cystic fibrosis
published pages: , ISSN: 2045-2322, DOI: 10.1038/s41598-018-34960-0
Scientific Reports 8/1 2019-12-17
2015 Justin S. Antony, Alexander Dewerth, Ashiqul Haque, Rupert Handgretinger, Michael S.D. Kormann
Modified mRNA as a new therapeutic option for pediatric respiratory diseases and hemoglobinopathies
published pages: , ISSN: 2194-7791, DOI: 10.1186/s40348-015-0022-6
Molecular and Cellular Pediatrics 2/1 2019-05-29
2016 Franziska Zeyer, Benedikt Mothes, Clara Will, Melanie Carevic, Jennifer Rottenberger, Bernd Nürnberg, Dominik Hartl, Rupert Handgretinger, Sandra Beer-Hammer, Michael S. D. Kormann
mRNA-Mediated Gene Supplementation of Toll-Like Receptors as Treatment Strategy for Asthma In Vivo
published pages: e0154001, ISSN: 1932-6203, DOI: 10.1371/journal.pone.0154001
PLOS ONE 11/4 2019-05-29
2016 Satheesh Elangovan,corresponding author1 Michael S.D. Kormann,2 Behnoush Khorsand,3 and Aliasger K. Salemcorresponding author1,3
The Oral and Craniofacial Relevance of Chemically Modified RNA Therapeutics
published pages: , ISSN: 1539-6509, DOI:
Discovery Medicine 2019-05-29

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "BREATHE" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "BREATHE" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.1.1.)

evolSingleCellGRN (2019)

Constraint, Adaptation, and Heterogeneity: Genomic and single-cell approaches to understanding the evolution of developmental gene regulatory networks

Read More  

HEIST (2020)

High-temperature Electrochemical Impedance Spectroscopy Transmission electron microscopy on energy materials

Read More  

IMMUNOTHROMBOSIS (2019)

Cross-talk between platelets and immunity - implications for host homeostasis and defense

Read More